New AI tools offer hope for global TB elimination
Researchers have unveiled new AI tools, from smartphone cough analysis to child-friendly screening systems, which could transform how…
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
MannKind MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation…
Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors
Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major…
Home rehab program improves lung function in bronchiectasis
A simple at-home program with daily exercise, airway clearance, and nurse support helps patients breathe easier, offering new…